6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy

VIALE-C compared the safety and efficacy of venetoclax or placebo plus low-dose cytarabine (+LDAC) in patients with untreated AML ineligible for intensive chemotherapy. Overall, 211 patients were enrolled (n = 143, venetoclax; n = 68, placebo). At the primary analysis, the study did not meet its pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Andrew H., Panayiotidis, Panayiotis, Montesinos, Pau, Laribi, Kamel, Ivanov, Vladimir, Kim, Inho, Novak, Jan, Stevens, Don A., Fiedler, Walter, Pagoni, Maria, Bergeron, Julie, Ting, Stephen B., Hou, Jing-Zhou, Anagnostopoulos, Achilles, McDonald, Andrew, Murthy, Vidhya, Yamauchi, Takahiro, Wang, Jianxiang, Chyla, Brenda, Sun, Yan, Jiang, Qi, Mendes, Wellington, Hayslip, John, DiNardo, Courtney D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486817/
https://www.ncbi.nlm.nih.gov/pubmed/34599139
http://dx.doi.org/10.1038/s41408-021-00555-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486817/
https://www.ncbi.nlm.nih.gov/pubmed/34599139
http://dx.doi.org/10.1038/s41408-021-00555-8

Ejemplares similares